McKesson Corporation (MCK)
594.02
8.94 (1.53%)
At close: Jan 14, 2025, 3:59 PM
593.73
-0.05%
After-hours Jan 14, 2025, 07:00 PM EST
undefined% (undefined)
| Bid | 488.88 |
| Market Cap | 75.40B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 19.42 |
| PE Ratio (ttm) | 30.59 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 630 |
| Volume | 652,186 |
| Avg. Volume (20D) | 823,354 |
| Open | 586.47 |
| Previous Close | 585.08 |
| Day's Range | 580.76 - 594.33 |
| 52-Week Range | 464.42 - 637.51 |
| Beta | undefined |
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management,...
Industry Medical - Distribution
Sector Healthcare
IPO Date Nov 10, 1994
Employees 45,000
Stock Exchange NYSE
Ticker Symbol MCK
Website https://www.mckesson.com
Analyst Forecast
According to 14 analyst ratings, the average rating for MCK stock is "Buy." The 12-month stock price forecast is $650, which is an increase of 9.42% from the latest price.
Buy 78.57%
Hold 14.29%
Sell 0.00%
Next Earnings Release
McKesson Corporation is scheduled to release its earnings on Feb 5, 2025,
after market closes.
Analysts project revenue of $95.87B, reflecting a 18.51% YoY growth and earnings per share of 8.47, making a 9.43% increase YoY.
Analysts project revenue of $95.87B, reflecting a 18.51% YoY growth and earnings per share of 8.47, making a 9.43% increase YoY.
2 months ago ·
Source
+10.6%
McKesson shares are trading higher after the compa...
Unlock content with
Pro Subscription
2 months ago ·
Source
+4.57%
McKesson shares are trading higher after the company reported better-than-expected Q2 financial results.
